| 3.1M |
| $11.8M |
| +9.5% |
| 5.518% |
| 0.00% |
| 4 | Velan Capital Investment Management LP | 2.8M | $10.9M | +0.4% | 5.061% | 6.62% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | $8.8M | +8.6% | 4.093% | 0.00% |
| 6 | Blackstone Inc. | 2.3M | $8.7M | 0.0% | 4.031% | 0.02% |
| 7 | ORBIMED ADVISORS LLC | 2.2M | $8.5M | — | 3.950% | 0.16% |
| 8 | Sio Capital Management, LLC | 1.9M | $7.3M | -2.4% | 3.419% | 1.21% |
| 9 | ACORN CAPITAL ADVISORS, LLC | 1.8M | $6.7M | 0.0% | 3.117% | 1.83% |
| 10 | Integral Health Asset Management, LLC | 1.5M | $5.7M | -14.3% | 2.669% | 0.23% |
| 11 | 5AM Venture Management, LLC | 1.4M | $5.2M | 0.0% | 2.437% | 1.82% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $5.1M | +12.7% | 2.360% | 0.00% |
| 13 | CITADEL ADVISORS LLC | 1.2M | $4.7M | -0.0% | 2.193% | 0.00% |
| 14 | STATE STREET CORP | 1.1M | $4.1M | +6.3% | 1.901% | 0.00% |
| 15 | Qube Research & Technologies Ltd | 1.0M | $4.0M | +490.7% | 1.860% | 0.00% |
| 16 | BALYASNY ASSET MANAGEMENT L.P. | 1.0M | $3.9M | — | 1.827% | 0.00% |
| 17 | BAKER BROS. ADVISORS LP | 972K | $3.7M | 0.0% | 1.729% | 0.02% |
| 18 | ADAR1 Capital Management, LLC | 941K | $3.6M | 0.0% | 1.673% | 0.16% |
| 19 | BANK OF AMERICA CORP /DE/ | 882K | $3.4M | -4.7% | 1.570% | 0.00% |
| 20 | MARSHALL WACE, LLP | 701K | $2.7M | +1281.8% | 1.247% | 0.00% |
| 21 | DIMENSIONAL FUND ADVISORS LP | 683K | $2.6M | +28.6% | 1.216% | 0.00% |
| 22 | NORTHERN TRUST CORP | 552K | $2.1M | +47.3% | 0.983% | 0.00% |
| 23 | Point72 Asset Management, L.P. | 549K | $2.1M | -52.4% | 0.977% | 0.00% |
| 24 | GOLDMAN SACHS GROUP INC | 546K | $2.1M | +37.3% | 0.972% | 0.00% |
| 25 | Catalio Capital Management, LP | 520K | $2.0M | -10.3% | 0.925% | 0.37% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in TARA — a direct measure of their conviction.
| 78.12% |
| 8.32 pp |
| $123M |
| 19% |
| Q4 2024 | 58 | +66% | 86.44% | +69.06 pp | $151M | +750% |
| Q3 2024 | 35 | — | 17.38% | — | $18M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
24 institutions opened new positions in TARA during Q2 2026, while 17 fully exited. 23 added to existing positions and 71 trimmed.
TARA institutional ownership fell by 5.41 percentage points quarter-over-quarter, with a net change of +5 holders.
The top 10 institutions account for 57.0% of all reported 13F value in TARA, and the top 25 account for 86.1%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Protara Therapeutics, Inc. (TARA) Institutional Ownership